Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ACHIEVE LIFE SCIENCES, INC.

(ACHV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/13/2021 10/14/2021 10/15/2021 10/18/2021 10/19/2021 Date
8.21(c) 8.3(c) 8.05(c) 7.89(c) 7.965 Last
42 716 31 071 52 876 57 925 67 379 Volume
-2.38% +1.10% -3.01% -1.99% +0.95% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 0,03 M - -
Net income 2021 -40,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -1,65x
Yield 2021 -
Sales 2022 0,70 M - -
Net income 2022 -39,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,36x
Yield 2022 -
Capitalization 75,3 M 75,3 M -
Capi. / Sales 2021 2 259x
Capi. / Sales 2022 107x
Nbr of Employees 13
Free-Float 99,6%
More Financials
Company
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action... 
More about the company
Ratings of Achieve Life Sciences, Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about ACHIEVE LIFE SCIENCES, INC.
10/04ACHIEVE LIFE SCIENCES : Alliance Global Partners Starts Achieve Life Sciences at Buy with ..
MT
09/15ACHIEVE LIFE SCIENCES : to Participate in Upcoming Investor Conferences
PU
09/14ACHIEVE LIFE SCIENCES : Announces Presentation of Cytisinicline Data at the 21st Annual So..
PU
09/09ACHIEVE LIFE SCIENCES : to Participate in Two Upcoming Investor Conferences
PU
08/23Certain Common Stock of Achieve Life Sciences, Inc. are subject to a Lock-Up Agreement ..
CI
08/23Certain Options of Achieve Life Sciences, Inc. are subject to a Lock-Up Agreement Endin..
CI
08/23Certain Restricted Stock Units of Achieve Life Sciences, Inc. are subject to a Lock-Up..
CI
08/23Certain Warrants of Achieve Life Sciences, Inc. are subject to a Lock-Up Agreement Endi..
CI
08/13ACHIEVE LIFE SCIENCES : Announces Expansion of Cytisinicline Clinical Operations Team and ..
PU
08/12ACHIEVE LIFE SCIENCES : Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/12ACHIEVE LIFE SCIENCES : Reports Financial Results for Second Quarter 2021 and Provides Cor..
PU
08/12ACHIEVE LIFE SCIENCES, INC. : Results of Operations and Financial Condition, Financial Sta..
AQ
08/12Achieve Life Sciences, Inc. Reports Earnings Results for the Second Quarter Ended June ..
CI
08/12ACHIEVE LIFE SCIENCES : Reports Financial Results for Second Quarter 2021 and Provides Cor..
PU
08/11ACHIEVE LIFE SCIENCES : Announces Two Patents Granted by USPTO for Novel Cytisinicline Dos..
PU
More news
News in other languages on ACHIEVE LIFE SCIENCES, INC.

- No features available -

More news
Analyst Recommendations on ACHIEVE LIFE SCIENCES, INC.
More recommendations
Chart ACHIEVE LIFE SCIENCES, INC.
Duration : Period :
Achieve Life Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACHIEVE LIFE SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 7,97 $
Average target price 35,25 $
Spread / Average Target 343%
EPS Revisions
Managers and Directors
John A. Bencich Chief Executive Officer & Director
Cindy A. Jacobs President, Chief Medical Officer & Director
Richard Alistair Balfour Stewart Executive Chairman
Anthony John Clarke Chief Scientific Officer
Martin A. Mattingly Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ACHIEVE LIFE SCIENCES, INC.-1.67%75
MODERNA, INC.219.34%135 157
LONZA GROUP AG27.29%58 232
IQVIA HOLDINGS INC.38.99%47 608
SEAGEN INC.-0.54%31 287
CELLTRION, INC.-39.28%24 952